Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2632-2642

  Watanabe, Mika ^a   Kato, Jun ^a   Inoue, Izumi ^a   Yoshimura, Noriko ^b   Yoshida, Takeichi ^a   Mukoubayashi, Chizu ^a   Deguchi, Hisanobu ^a   Enomoto, Shotaro ^a   Ueda, Kazuki ^a   Maekita, Takao ^a   Iguchi, Mikitaka ^a   Tamai, Hideyuki ^a   Utsunomiya, Hirotoshi ^a   Yamamichi, Nobutake ^b   Fujishiro, Mitsuhiro ^b   Iwane, Masataka ^c   Tekeshita, Tatsuya ^a   Mohara, Osamu ^c   Ushijima, Toshikazu ^d   Ichinose, Masao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Wakayama Wellness Foundation   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

diffuse type gastric cancer; giant fold; Helicobacter pylori; pepsinogen; rugal hyperplastic gastritis

Indexed keywords

AMOXICILLIN; BACTERIUM ANTIBODY; CLARITHROMYCIN; HELICOBACTER PYLORI ANTIBODY; OMEPRAZOLE; PEPSINOGEN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; ENDOSCOPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RUGAL HYPERPLASTIC GASTRITIS; SEROLOGY; STOMACH CANCER;

ANTIBODIES, BACTERIAL; COHORT STUDIES; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERPLASIA; INCIDENCE; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPSINOGEN A; RISK FACTORS; STOMACH; STOMACH NEOPLASMS;

EID: 84867056338     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27514     Document Type: Article

References (50)

1. Vital Statistics of Japan. Statistics and Information Dept., Minister's Secretariat, Ministry of Health, Labour and Welfare 2009; 1: 300-1.
2. Hamilton S, Aaltonen L, eds. Pathology and genetics. Tumors of the digestive system. WHO classification of tumours. Lyon: IARC Press, 2000.
3. Correa P,. Human gastric carcinogenesis: a multi-step and multi-factorial process, First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
4. Correa P, Houghton J,. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-72.
5. Nardone G, Rocco A, Malfertheiner P,. Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther 2004; 20: 261-70.
6. Siurala M, Varis K, Wiljasalo M,. Studies on patients with atrophic gastritis: a 10-15 year follow-up. Scand J Gastroenterol 1966; 1: 40-8.
7. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M,. Gastric cancer risk in chronic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-7.
8. Testoni PA, Masci E, Marchi R, Guslandi M, Ronchi G, Tittobello A,. Gastric cancer in chronic atrophic gastritis. Associated gastric ulcer adds no further risk. J Clin Gastroenterol 1987; 9: 298-302.
9. Tatsuta M, Iishi H, Nakaizumi A, Okuda S, Taniguchi H, Hiyama T, Tsukuma H, Oshima A,. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 1993; 53: 70-4.
10. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ,. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
11. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 138-43.
12. Yanaoka K, Oka M, Yoshimura N, Mukoubayashi C, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Yamamichi N, Fujishiro M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17: 838-45.
13. Yanaoka K, Oka M, Yoshimura N, Mukoubayashi C, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Yamamichi N, Fujishiro M, et al. Risk of gastric cancer development in asymptomatic middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008; 123: 917-26.
14. Inoue M, Tajima K, Matsuura A, Suzuki T, Nakamura T, Ohashi K, Nakamura S, Tominaga S,. Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Lett 2000; 161: 105-12.
15. Vauhkonen M, Vauhkonen H, Sipponen P,. Pathology and molecular biology of gastric cancer. Best Prac Res Clin Gastroenterol 2006; 20: 651-74.
16. Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Tamai H, Arii K, Nakata H, et al. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci 2005; 96: 713-20.
17. Sipponen P, Kosunen TU, Valle J, Riihela M, Seppala K,. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992; 45: 319-23.
18. Karnes WE, Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH,. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167-74.
19. Farinati F, Valiante F, Germana B, Della Libera G, Baffa R, Rugge M, Plebani M, Vianello F, Di Mario F, Naccarato R,. Prevalence of Helicobacter pylori infection in patients with precancerous changes and gastric cancer. Eur J Cancer Prev 1993; 2: 321-6.
20. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS,. Stomach carcinoma incidence patterns in the United states by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 2009; 18: 1945-52.
21. Kaneko S, Yoshimura T,. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001; 84: 400-5.
22. Morrison S, Dahms BB, Hoffenberg E, Czinn SJ,. Enlarged gastric folds in association with Campylobacter pylori gastritis. Radiology 1989; 171: 819-21.
23. Stolte M, Bätz CH, Eidt S,. Giant fold gastritis-a special form of Helicobacter pylori associated gastritis. Z Gastroenterol 1993; 31: 289-93.
24. Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Yasunaga Y, Nishibayashi H, Yamamori K, Higashimoto Y, Matsuzawa Y,. Morphological and functional restoration of parietal cells in Helicobacter pylori associated enlarged fold gastritis after eradication. Gut 1999; 45: 653-61.
25. Stolte M, Bätz CH, Bayerdörffer E, Eidt S,. Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach. Z Gastroenterol 1995; 33: 198-201.
26. Tytgat GN,. The Sydney system: endoscopic division. Endoscopic appearance in gastritis/duodenitis. J Gastroenterol Hepatol 1991; 6: 223-34.
27. Yasunaga Y, Shinomura Y, Kanayama S, Higashimoto Y, Yabu M, Miyazaki Y, Kondo S, Murayama Y, Nishibayashi H, Kitamura S, Matsuzawa Y,. Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut 1996; 39: 787-94.
28. Nishibayashi H, Kanayama S, Kiyohara T, Yamamoto K, Miyazaki Y, Yasunaga Y, Shinomura Y, Takeshita T, Takeuchi T, Morimoto K, Matsuzawa Y,. Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. J Gastroenterol Hepatol 2003; 18: 1384-91.
29. Ohyama I, Ohmiya N, Niwa Y, Shirai K, Taguchi A, Itoh A, Hirooka Y, Wakai K, Hamajima N, Mori N, Goto H,. The association between tumour necrosis factor-alpha gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. Eur J Gastroenterol Hepatol 2004; 43: 653-6.
30. Oguri A, Ohmiya N, Taguchi A, Itoh A, Hirooka Y, Niwa Y, Maeda O, Ando T, Goto H,. Rugal hyperplastic gastritis increases the risk of gastric carcinoma, especially diffuse and p53-independent subtypes. Eur J Gastroenterol Hepatol 2007; 19: 561-6.
31. Suzuki M, Suzuki H, Minegishi Y, Ito K, Nishizawa T, Hibi T,. H. pylori-eradication therapy increases RUNX3 expression in the glandular epithelial cells in enlarged-fold gastritis. J Clin Biochem Nutr 2010; 46: 259-64.
32. Lauren P,. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
33. Ichinose M, Miki K, Furihata C, Kageyama T, Hayashi R, Niwa H, Oka H, Matsushima T, Takahashi K,. Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin Chim Acta 1982; 126: 183-91.
34. Chen TS, Chang FY, Lee SD,. Serodiagnosis of Helicobacter pylori infection: comparison and correlation between enzyme-linked immunosorbent assay and rapid serological test results. J Clin Microbiol 1997; 35: 184-6.
35. Plebani M, Basso D, Cassaro M, Brigato L, Scrigner M, Toma A, Di Mario F, Rugge M,. Helicobacter pylori serology in patients with chronic gastritis. Am J Gastroenterol 1996; 91: 954-8.
36. Loffeld RJ, Werdmuller BF, Kusters JG, Kuipers EJ,. IgG antibody titer against Helicobacter pylori correlates with presence of cytotoxin associated gene A-positive H. pylori strains. FEMS Immunol Med Microbiol 2000; 28: 139-41.
37. Balthazar EJ, Davidian MM,. Hyperrugosity in gastric carcinoma: radiographic, endoscopic, and pathologic features. Am J Roentgenol 1981; 136: 531-5.
38. Rohrmann CA Jr, Seaman WB,. Nonneoplastic lesions of the stomach. In:, Alexander R, Margulis H, Burhenne J, eds. Alimentary tract radiology. St Louis: Mosby, 1989. 551-93.
39. Miyazaki T, Murayama Y, Shinomura Y, Yamamoto T, Watabe K, Tsutsui S, Kiyohara T, Tamura S, Hayashi N,. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter 2007; 12: 523-31.
40. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae, and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-95.
41. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T,. Inflammatory process triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70: 1430-40.
42. Ushijima T, Sasako M,. Focus on gastric cancer. Cancer Cell 2004; 5: 121-5.
43. Tamura G,. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-8.
44. Kusano M, Toyota M, Suzuki H, Akino K, Aoki F, Fujita M, Hosokawa M, Shinomura Y, Imai K, Tokino T,. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467-79.
45. Yamaoka Y,. Helicobacter pylori typing as a tool for tracking human migration. Clin Microbiol Infect 2009; 15: 829-34.
46. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WHC, Yuen ST, Leung SY, Fong DYT, Ho J, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-94.
47. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, Ueda K, Utsunomiya H, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009; 125: 2697-703.
48. Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, Kwong YL, Rashid A, Chan CK, Wong BC,. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006; 55: 463-8.
49. Leung WK, Man EP, Yu J, Go MY, To KF, Yamaoka Y, Cheng VY, Ng EK, Sung JJ,. Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clin Cancer Res 2006; 12: 3216-21.
50. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M,. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-8.